Investigating gut microbiota and genetics in inflammatory bowel diseases
Official title: Investigating the Intestinal Microbiota, Epigenetic Markers and Body Fluid Metabolites to Identify Biomarkers for Inflammatory Bowel Diseases
Run by Chinese University of Hong Kong · NCT03855657 · Data updated 2026-11-12
This study is trying to understand how gut bacteria and genetics affect inflammatory bowel diseases like ulcerative colitis and Crohn's disease, to help improve treatment for patients.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 6000 (estimated) |
| Sponsor | Chinese University of Hong Kong Academic / other |
| Locations | 1 site (Hong Kong) |
| Status | Recruiting |
| Started | March 2014 |
| Main results expected | February 2034 |
| Study ends | July 2034 |
| Registry record updated | February 8, 2023 |
| Trial ID | NCT03855657 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are adults aged 18 and older diagnosed with Crohn's disease or ulcerative colitis.
✕Probably not a fit
Patients with known current infections or those with a family history of IBD may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to establish a large-scale biobank to investigate the gut microbiota, genetics, epigenetics, and metabolites associated with inflammatory bowel diseases (IBD), specifically ulcerative colitis and Crohn's disease. It addresses the rising incidence of IBD in Asia and seeks to understand the interplay between genetic predisposition and environmental factors in disease development. By collecting comprehensive clinical data from patients, the study aims to personalize therapy and improve treatment outcomes for IBD patients.
Why it matters
Potential benefit: If successful, this study could lead to more personalized and effective treatment strategies for patients with inflammatory bowel diseases.
How similar studies have gone: Other studies have shown success in utilizing biobanks to investigate complex diseases, suggesting that this approach could yield valuable insights into IBD.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patient ≥18 with a diagnosis of Crohn's disease or ulcerative colitis * Informed Consent obtained Exclusion Criteria: * Known current infection with an enteric pathogen * Previously been diagnosed with IBD (Control) * Have a first of second degree relative with IBD (Control)
Where it's running
-
Prince of Wales Hospital
Hong Kong, Hong Kong Recruiting
Study contacts
- Principal investigator: Siew Chien Ng, PhD — Chinese University of Hong Kong
- Study coordinator: Siew Chien Ng, PhD
- Email: siewchienng@cuhk.edu.hk
- Phone: 852-35053996
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Long-Term Guselkumab Use in Adults with Inflammatory Bowel Disease
This study looks at how long adults with Crohn's disease or ulcerative colitis stay on guselkumab in real-world care.
-
Intestinal ultrasound-guided management for inflammatory bowel disease
This study tests if adding point-of-care intestinal ultrasound at every visit changes treatment decisions for adults with Crohn’s disease or ulcerative colitis undergoing disease assessment.
-
Resting energy use in kids with inflammatory bowel disease
This multicenter study will test the resting energy expenditure of children aged 6–17 with new IBD diagnoses to see how it relates to disease activity and treatment.
-
Active video education by disease subtype to improve bowel prep before colonoscopy
We’re testing whether adding subtype-specific video education to standard prep improves bowel cleanliness in adults with IBD undergoing colonoscopy.
-
Intestinal ultrasound to predict relapse in Crohn's disease patients in deep remission.
This project will try to see if a noninvasive transabdominal ultrasound can predict relapses in adults with Crohn's disease who are currently in deep remission.
-
Ath-063: Testing a new treatment for moderately to severely active ulcerative colitis in patients who have tried other biologics
This study tests ATH-063 to see if it helps people with moderate to severe ulcerative colitis who did not respond to or relapsed after prior biologic therapy.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.